Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)
Close on Nov 17, 2026Market cap $206.32MP/E –Yield –
Lineage Cell Therapeutics market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Lineage Cell Therapeutics's market cap was $280.73M on Nov 11, 2026, against $405.38M a year earlier. Over the last 5 years it ranged from $94.89M to $466.79M, with a median of $234.25M.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $280.73M | -27.0% |
| 2025 | Dec 31, 2025 | $384.65M | +305.4% |
| 2024 | Dec 31, 2024 | $94.89M | -50.3% |
| 2023 | Dec 29, 2023 | $190.74M | -4.0% |
| 2022 | Dec 30, 2022 | $198.77M | -51.8% |
| 2021 | Dec 31, 2021 | $412.74M | +56.3% |
| 2020 | Dec 31, 2020 | $263.98M | +98.0% |
| 2019 | Dec 31, 2019 | $133.31M | +15.1% |
| 2018 | Dec 31, 2018 | $115.85M | -53.5% |
| 2017 | Dec 29, 2017 | $248.98M | -32.9% |
| 2016 | Dec 30, 2016 | $371.01M | +10.3% |
| 2015 | Dec 31, 2015 | $336.38M | +32.1% |
| 2014 | Dec 31, 2014 | $254.73M | +27.2% |
| 2013 | Dec 31, 2013 | $200.24M | +29.7% |
| 2012 | Dec 31, 2012 | $154.37M | -45.7% |
| 2011 | Dec 30, 2011 | $284.41M | – |
See a number that looks wrong?